EMEA-002031-PIP01-16

  • Email
  • Help

Overview

Product details for -
Invented name-
Active substance

Emapalumab

Decision numberP/0358/2017
PIP numberEMEA-002031-PIP01-16
Pharmaceutical form(s)Concentrate for solution for infusion
Condition(s)/indication(s)

Treatment of haemophagocytic lymphohistiocytosis

Route(s) of administrationIntravenous use
PIP applicant

Novimmune B.V.
Tel. +41 228397141
E-mail: pip@novimmune.com

Decision typeP: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision